|
Schwarz Biosciences is sponsoring a multi-site clinical trial for persons 16 to 70 years with a diagnosis of partial seizures. Persons who meet the study criteria and are willing to participate will receive either 300 mg per day or 400 mg per day of Lacosamide for up to 20 weeks with a potential option to enter an open-label trial. Study visits and study medication costs will be covered by the Sponsor (Schwarz). Persons interested in getting more detailed study information should e-mail the study coordinator for the LSU Epilepsy Center of Excellence in New Orleans at epicenter@lsuhsc.edu. Please provide your name, e-mail address or telephone number and the study in which you are interested.
Pfizer is sponsoring a clinical trial at the LSUHSC Epilepsy Center in New Orleans where eligible candidates will be 18 years or older and experiencing partial epileptic seizures. Those meeting the additional study criteria and willing to participate will receive one of two doses of the study drug for 20 weeks as treatment for their partial seizures. Study visits and study medication costs will be covered by the Sponsor. At the end of the study, there may be an option to extend treatment with the study drug for about 6 months. Anyone interested in getting more detailed study information should e-mail the study coordinator at epicenter@lsuhsc.edu. Please provide your name, e-mail address or telephone number and the study in which you are interested.
The listing of epilepsy clinical trials is for information purposes only; and the reader assumes full responsibility and risk for the appropriate use of the information provided. The information concerning the trial has been provided by the investigator; the Epilepsy Foundation, its affiliates, officers, directors, employees, and agents do not warrant or guarantee the accuracy or completeness of the information and specifically disclaims any liability therefore.
|
